To move our results closer to the clinic and measure the effect of ATG7 knockdown, alone or in combination with TKI treatment, on expansion of CP CML CD34+ cells, GFP sorted cells were left untreated or treated with nilotinib or dasatinib for 3 d. This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.